Treatment of Advanced or Metastatic Typical Lung Carcinoid and Slowly Progressing SRI-Positive Lung Carcinoid

This protocol addresses patients with advanced or metastatic typical lung carcinoid (TC), or with slowly progressing, somatostatin receptor imaging (SRI)-positive lung carcinoid — a distinct clinical subset of pulmonary neuroendocrine tumors requiring a specific management approach.

Eligible patients present with advanced or metastatic typical lung carcinoid, or with slowly progressing SRI-positive lung carcinoid. Somatostatin analogues (SSAs) are recommended as first-line treatment in these patients. In asymptomatic patients with slowly and radiologically progressing disease, watchful follow-up may also be considered as part of the initial management strategy.

Approach (partial overview) A targeted systemic agent is recommended for patients with progressive or advanced lung carcinoid in this setting — the complete protocol specifies the agent, the precise patient population, and the circumstances under which it is indicated.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2021.01.003

SSAs are recommended first-line treatment in patients with TC and/or slowly progressing advanced SRI-positive LC and ThC [IV, C]

Watchful follow-up may be considered in asymptomatic patients with slowly radiologically progressing LCs [V, C]

Everolimus is recommended either as first line in case of AC or, second-line post-SSA, in patients with TC and or progressive advanced LCs and ThCs [II, B]

View source ↗